MML Investors Services
CPRX

MML Investors Services’s Catalyst Pharmaceutical CPRX Stock Holding History

MML Investors Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$532K Buy
21,495
+8,287
+63% +$197K ﹤0.01% 2177
2025
Q4 		$308K Sell
13,208
-15,327
-54% -$341K ﹤0.01% 2600
2025
Q3 		$562K Buy
28,535
+5,924
+26% +$122K ﹤0.01% 2089
2025
Q2 		$491K Buy
+22,611
New +$534K ﹤0.01% 2109
2022
Q3 		– Sell
-11,621
Closed -$81K – 2090
2022
Q2 		$81K Buy
+11,621
New +$85.2K ﹤0.01% 1987

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

MML Investors Services's CPRX Position: Q1 2026 in Review

MML Investors Services increased its Catalyst Pharmaceutical (CPRX) stake by 63% in Q1 2026, buying an estimated $197K and bringing the position to 21,495 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

MML Investors Services first reported a position in CPRX in Q2 2022 and has held it in 5 quarters since. The position peaked at $562K in Q3 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • MML Investors Services held 21,495 shares of Catalyst Pharmaceutical worth $532K as of Q1 2026.
  • MML Investors Services bought 8,287 Catalyst Pharmaceutical shares in Q1 2026, an estimated $197K.
  • Catalyst Pharmaceutical made up ﹤0.01% of MML Investors Services's portfolio in Q1 2026, its #2177 holding.
  • MML Investors Services first reported a position in Catalyst Pharmaceutical in Q2 2022 and has held it in 5 quarters since.
  • MML Investors Services's Catalyst Pharmaceutical position peaked at $562K in Q3 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.